PHASE-II TRIAL OF FLUTAMIDE IN HYPER-NEPHROMA CORRELATION WITH HORMONE RECEPTOR-SITES

被引：0
|
作者：
BENEDETTO, P
YAGODA, A
WATSON, RC
SOGANI, P
NERI, RO
PERTSCHUK, LP
FISHMAN, J
BRADLOW, JL
机构：
[1] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
[2] ROCKEFELLER UNIV,NEW YORK,NY 10021
[3] SUNY DOWNSTATE MED CTR,BROOKLYN,NY 11203
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1981年 / 22卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：466 / 466
页数：1
相关论文
共 50 条
  • [11] PHASE-II TRIAL OF FLUTAMIDE IN ADVANCED OVARIAN-CANCER - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY
    TUMOLO, S
    RAO, BR
    VANDERBURG, ME
    GUASTALLA, JP
    RENARD, J
    VERMORKEN, JB
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (07) : 911 - 914
  • [12] PHASE-II TRIAL OF ECHINOMYCIN IN ADVANCED HORMONE-RESISTANT PROSTATE-CANCER
    SHEVRIN, DH
    LAD, TE
    GUINAN, P
    KILTON, LJ
    GREENBURG, A
    JOHNSON, P
    BLOUGH, RR
    HOYER, H
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (01) : 65 - 66
  • [13] Docetaxel and mitoxantron in the management of hormone refractory prostate cancer: Results of a prospective phase-II trial
    Heidenreich, A
    Wille, S
    Ohlmann, C
    Elert, A
    Hofmann, R
    JOURNAL OF UROLOGY, 2003, 169 (04): : 399 - 399
  • [14] TRIMETREXATE IN ADVANCED HORMONE-REFRACTORY PROSTATE-CANCER - AN ECOG PHASE-II TRIAL
    WITTE, RS
    YEAP, BY
    TRUMP, DL
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (03) : 255 - 258
  • [15] PHASE-II TRIAL OF IFOSFAMIDE IN THE TREATMENT OF METASTATIC HORMONE-REFRACTORY PATIENTS WITH PROSTATIC-CANCER
    MAHJOUBI, M
    AZAB, M
    GHOSN, M
    THEODORE, C
    DROZ, JP
    CANCER INVESTIGATION, 1990, 8 (05) : 477 - 481
  • [16] A BROAD PHASE-II TRIAL OF AMSA WITH INVITRO STEM-CELL CULTURE DRUG SENSITIVITY CORRELATION
    AHMANN, F
    MEYSKENS, F
    JONES, S
    DURIE, B
    ALBERTS, D
    SALMON, S
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 369 - 369
  • [17] Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
    Paul, Devchand
    Vukelja, Svetislava J.
    Holmes, Frankie Ann
    Blum, Joanne L.
    McIntyre, Kristi J.
    Lindquist, Deborah L.
    Osborne, Cynthia R.
    Sanchez, Ines J.
    Goldschmidt, Jerome H.
    Wang, Yunfei
    Asmar, Lina
    Strauss, Lewis
    O'Shaughnessy, Joyce
    NPJ BREAST CANCER, 2019, 5 (1)
  • [18] Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
    Devchand Paul
    Svetislava J. Vukelja
    Frankie Ann Holmes
    Joanne L. Blum
    Kristi J. McIntyre
    Deborah L. Lindquist
    Cynthia R. Osborne
    Ines J. Sanchez
    Jerome H. Goldschmidt
    Yunfei Wang
    Lina Asmar
    Lewis Strauss
    Joyce O’Shaughnessy
    npj Breast Cancer, 5
  • [19] TAXOL IN ADVANCED, HORMONE-REFRACTORY CARCINOMA OF THE PROSTATE - A PHASE-II TRIAL OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP
    ROTH, BJ
    YEAP, BY
    WILDING, G
    KASIMIS, B
    MCLEOD, D
    LOEHRER, PJ
    CANCER, 1993, 72 (08) : 2457 - 2460
  • [20] A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases.
    Xu, Jing
    Higgins, Michaela Jane
    Tolaney, Sara M.
    Come, Steven E.
    Smith, Matthew Raymond
    Fornier, Monica N.
    Mahmood, Umar
    Yeap, Beow Y.
    Chabner, Bruce Allan
    Isakoff, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345